In the IV injection groups, elevated miR2911 levels, suppressed expression of TGF-β1, decreased hepatic hydroxyproline levels and alleviated liver fibrosis were all observed in the livers of both Sidt1+/+ and Sidt1−/− mice (Fig. 6b–f). This evidence concerns the gene TGFB1 and Hepatic fibrosis.